Investors
Information for investors including share information, share analysis, shareholder news and annual reports.
Q1 2013 results: 24 Apr 2013
View Q1 results details and CFO video
Reasons to invest in GlaxoSmithKline - a leading pharmaceutical company enabling people to do more, feel better and live longer.
Find out how GSK is performing with our Annual Report, Corporate Responsibility Report and financial summary.
Press releases
GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics
GlaxoSmithKline (GSK) plc and the Biomedical Advanced Research and Development Authority (BARDA), have agreed to a first of its kind collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism.
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
GSK and Save the Children form unique partnership to save the lives of one million children
An ambitious new partnership to save the lives of a million of the poorest children in the world has been launched by GSK and Save the Children.
| GlaxoSmithKline plc |
Tel: 020 8047 5000 |
| 980 Great West Road |
Fax: 020 8047 7807 |
| Brentford |
|
| Middlesex TW8 9GS |
